NDI-101150

Nimbus Therapeutics has completed its IND submission for NDI-219216, a non-covalent WRN inhibitor, planned for a clinical trial in H1 2025.

HPK1 inhibition is emerging as a strategy to enhance T-cell functionality and improve immunotherapy efficacy in solid tumors, with several inhibitors in early-phase trials.

NDI-101150 monotherapy achieved an 18% objective response rate in heavily pretreated renal cell carcinoma (RCC) patients who had prior exposure to checkpoint inhibitors.

NDI-101150 monotherapy achieved an 18% objective response rate in heavily pretreated renal cell carcinoma (RCC) patients who had prior exposure to checkpoint inhibitors.

Nimbus Therapeutics' NDI-101150, an oral HPK1 inhibitor, is currently in Phase I/II clinical trials for advanced solid tumors, demonstrating potential in immuno-oncology.